NCT04485013 2026-02-18TTX-080 HLA-G Antagonist in Subjects With Advanced CancersTizona Therapeutics, IncPhase 1 Recruiting240 enrolled
NCT04682431 2024-03-22A Phase 1a/1b FIH Study of PY159 and in Combination With Pembrolizumab in Subjects With Advanced Solid TumorsIkena OncologyPhase 1 Terminated127 enrolled
NCT04691375 2024-03-22A Study of PY314 in Subjects With Advanced Solid TumorsIkena OncologyPhase 1 Terminated86 enrolled